Celtic Biotech is developing novel candidate therapies for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to increase survival, improve quality-of-life and reduce treatment costs for cancer patients. Celtic Biotech is focusing its research on solid tumours, including non-small-cell lung cancer (NSCLC), as its initial targets. The Company's lead candidate, CB24 (Crotoxin), has been observed to be highly toxic to various tumour cell lines in pre-clinical and early clinical studies.
View Top Employees from Celtic Biotech Ltd| Website | https://www.celticbiotech.com |
| Revenue | $3.8 million |
| Employees | 4 (2 on RocketReach) |
| Founded | 2003 |
| Industry | Biotechnology Research, Biotechnology, Therapeutic Devices, Pharmaceuticals, Other Devices and Supplies, Healthcare |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Celtic Biotech Ltd employee's phone or email?
Celtic Biotech Ltd Questions
The Celtic Biotech Ltd annual revenue was $3.8 million in 2023.
Paul Reid is the CEO of Celtic Biotech Ltd.
2 people are employed at Celtic Biotech Ltd.
Celtic Biotech Ltd is based in Dublin, County Dublin.
The NAICS codes for Celtic Biotech Ltd are [3254, 32, 325].
The SIC codes for Celtic Biotech Ltd are [283, 28].
Top Celtic Biotech Ltd Employees
-
35+
-
24
Related Companies
